Relationship Between Platelet Reactivity and Periprocedural Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention.
The impact of platelet reactivity on periprocedural myonecrosis (PMN) in East Asian patients with stable ischemic heart disease or non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention (PCI) is unclear. We enrolled 256 patients with normal high-sensitivity troponin I levels who underwent PCI for stable ischemic heart disease or non-ST elevation acute coronary syndrome. Residual platelet reactivity was assessed by VerifyNow point-of-care P2Y12 assay before PCI and at 18-24 hours following PCI. High platelet reactivity (HPR) was defined using three cut-off scores for platelet reactivity units (PRUs). PMN was defined as a high-sensitivity troponin I elevation of >5x the 99th percentile upper reference limit (URL) in patients with normal baseline values (<99th percentile URL). The rate of PMN was 55.9% (n = 143) and was significantly higher for pre-PCI and post-PCI PRU values in the fourth quartile compared with those in the first quartile (15% vs 37% [P<.001] and 20% vs 36% [P<.001], respectively). The rate of PMN was higher in patients with HPR, regardless of the criteria used (PRU >208, PRU >235, and PRU >272) and time point. Multivariable analysis revealed that pre-PCI HPR (PRU >208) was an independent predictor of increased risk of PMN (odds ratio, 3.39; 95% confidence interval, 1.87-6.17; P<.001). Pre-PCI HPR (PRU >208) was associated with an increased risk of PMN in East Asian patients with stable ischemic heart disease or non-ST elevation acute coronary syndrome undergoing PCI. Achievement of optimal platelet reactivity may decrease the risk of PMN.